A Diabetes Outcome Progression Trial (ADOPT): Baseline characteristics of Type 2 diabetic patients in North America and Europe

Diabetic Medicine

Volumn 23, Issue 12, 2006, Pages 1289-1294

  Viberti, G ^a   Lachin, J ^b   Holman, R ^c   Zinman, B ^d   Haffner, S ^e   Kravitz, B ^f   Heise, M A ^f   Jones, N P ^g   O'Neill, M C ^f   Freed, M I ^f   Kahn, S E ^h   Herman, W H ⁱ  

^a GUY S HOSPITAL   (United Kingdom)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c CHURCHILL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f GLAXOSMITHKLINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

ADOPT; Haemoglobin A1c; Phenotype; Race; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLIBENCLAMIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET THERAPY; DISEASE COURSE; ETHNIC DIFFERENCE; EUROPE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORTH AMERICA; OBESITY; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL;

ADULT; AGE DISTRIBUTION; AGED; BLOOD GLUCOSE; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; NORTH AMERICA; SEX DISTRIBUTION; THIAZOLIDINEDIONES;

EID: 33751240059     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.02022.x     Document Type: Article

References (19)

1. Pirart J, Lauvaux JP, Rey W. Blood sugar and diabetic complications. N Engl J Med 1978; 298: 1149.
2. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408.
3. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737-1743.
4. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000; 23: S32-S42.
5. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care 2004; 27: 1487-1495.
6. Hanson RL, Pratley RE, Bogardus C, Narayan KM, Roumain JM, Imperatore G et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000; 151: 190-198.
7. NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Expert Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
8. Snedecor GW, Cochran WG. Statistical Methods, 7th edn. Ames, IA: State University Press 1980.
9. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 1979; 6: 65-70.
10. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes. UK Prospective Diabetes Study 64. Kidney Int 2003; 63: 225-232.
11. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study. Diabetes Care 1987; 10: 1-19.
12. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia 1990; 33: 208-215.
13. Meigs JB, Nathan DM, Cupples LA, Wilson PW, Singer DE. Tracking of glycated haemoglobin in the original cohort of the Framingham-Heart Study. J Clin Epidemiol 1996; 49: 411-417.
14. Kilpatrick ES, Maylor PW, Keevil BG. Biological variation of glycated haemoglobin. Implications for diabetes screening and monitoring. Diabetes Care 1998; 21: 261-264.
15. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 1259-1264.
16. Saaddine JB, Fagot-Campagna A, Rolka D, Narayan KM, Geiss L, Eberhardt M, et al. Distribution of HBA(1c) levels for children and young adults in the US: Third National Health and Nutrition Examination Survey. Diabetes Care 2002; 25: 1326-1330.
17. deRekeneire N, Rooks RN, Simonsick EM, Shorr RI, Kuller LH, Schwartz AV, et al. Racial differences in glycemic control in a wellfunctioning older diabetic population: findings from the health, aging, and body composition study. Diabetes Care 2003; 26: 1986-1992.
18. Brown AF, Gerzoff RB, Karter AJ, Gregg E, Safford M, Waitzfelder B, et al. Health behaviours and quality of care among Latinos with diabetes in managed care. Am J Public Health 2003; 93: 1694-1698.
19. Genuth S, Lachin JM, Nathan DM. Comments and responses: biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2005; 28: 233.